RecruitingNot ApplicableNCT06056505
Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy
Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy - a Multicentre, Randomised, Controlled Trial
Sponsor
University of Leipzig
Enrollment
370 participants
Start Date
Oct 24, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The primary objective is to determine if 3D modelling shortens total console operation time as a surrogate endpoint for clinical outcomes like perioperative complications and morbidity in robotic-assisted partial nephrectomy.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Patients with kidney tumours ≤ 7cm and planned robotic-assisted partial nephrectomy with the DaVinci Surgical System
- CT scan with contrast medium available
- Age ≥ 18 years
- Written informed consent
Exclusion Criteria11
- History of surgery on affected kidney (e.g., partial nephrectomy, pyeloplasty, kidney cyst deroofing, percutaneous nephrolitholapaxy, radiofrequency ablation)
- Horseshoe kidney
- Previous malignancy with ongoing or planned nephrotoxic chemotherapy
- Patient is immunosuppressed (e.g., organ transplantation, leukaemia)
- Tumor thrombus in Vena renalis or Vena cava inferior
- Existing renal insufficiency GFR \< 15 ml/min/1.73m2
- Severe cognitive impairment
- Pregnancy or lactation or women with desire for children
- Patients under legal supervision or guardianship
- Unable to give informed consent or suspected lack of compliance
- Patients who refuse to data collection and storage for the main study
Interventions
PROCEDUREpartial kidney nephrectomy
surgery for partial nephrectomy
DEVICEDaVinci Robot
device to perform the surgery for partial nephrectomy (not the intervention of interest)
DEVICEInnersight 3D software
investigational product to generate the 3D model
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06056505
Related Trials
Engineering Immune Organoids to Study Pediatric Cancer
NCT058907812 locations
Decision Aid (DA) for Renal Patients
NCT053878631 location
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
NCT070534621 location
Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors
NCT057289571 location